Abstract
Phosphorothioate oligodeoxynucleotides (PODNs) can act as antisense molecules, knocking down proteins. Many PODNs have the unusual characteristic of being transported across the blood–brain barrier by a saturable system. This means that PODNs injected intravenously can accumulate in the central nervous system in quantities sufficient to knock down proteins in brain and the blood–brain barrier. A critical step in the development of PODNs that can be administered peripherally and knockdown proteins in the central nervous system is to determine the relation to the blood–brain barrier, specifically, does the PODN cross the blood–brain barrier and, if so, how fast and to what degree.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Phillips, M.I., and Gyorko, R. (1997) Antisense oligonucleotides: New tools for physiology. News Physiol. Sci. 12, 810–817.
Morley, J.E., Farr, S.A., Kumar, V.B., and Banks, W.A. (2002) Alzheimer’s disease through the eye of a mouse: Acceptance lecture for the 2001 Gayle A. Olson and Richard D. Olson prize. Peptides 23, 589–599.
Agrawal, S., Zhang, X., Lu, Z., Zhao, H., Tamburin, J.M., Yan, J. et al.(1995) Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol. 50, 571–576.
Boado, R.J., Tsukamoto, H., and Pardridge, W.M. (1998) Drug delivery of antisense molecules to the brain for treatment of Alzheimer’s disease and cerebral AIDS. J. Pharm. Sci. 87, 1308–1315.
Banks, W.A., Farr, S.A., Butt, W., Kumar, V.B., Franko, M.W., and Morley, J.E. (2001) Delivery across the blood-brain barrier of antisense directed against amyloid: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. J. Pharmacol. Exp. Ther. 297, 1113–1121.
Jaeger, L.B., Dohgu, S., Hwang, M.C., Farr, S.A., Murphy, M.P., Fleegal-DeMotta, M.A. et al. (2009) Testing the neurovascular hypothesis of Alzheimer’s disease: LRP-1 antisense reduced blood-brain barrier clearance, increases brain levels of amyloid beta protein, and impairs cognition. J. Alzheimers Dis. 17, 553–570.
Dogrukol-Ak, D., Kumar, V.B., Ryerse, J.S., Farr, S.A., Verma, S., Nonaka, N. et al. (2009) Isolation of peptide transport system-6 from brain endothelial cells: therapeutic effects with antisense inhibition in Alzheimer’s and stroke models. J. Cereb. Blood Flow Metab. 29, 411–422.
Banks, W.A., Jaeger, L.B., Urayama, A., Kumar, V.B., Hileman, S.M., Gaskin, F.S. et al. (2006) Preproenkephalin targeted antisenses cross the blood-brain barrier to reduce brain methionine enkephalin levels and increase voluntary drinking. Peptides 27, 784–796.
Poon, H.F., Joshi, G., Sultana, R., Farr, S.A., Banks, W.A., Morley, J.E. et al. (2004) Antisense directed at the A-beta region of APP decreases brain oxidative markers in aged senescence accelerated mice. Brain Res. 1018, 86–96.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Banks, W.A. (2011). Measurement of Phosphorothioate Oligodeoxynucleotide Antisense Transport Across the Blood–Brain Barrier. In: Merighi, A. (eds) Neuropeptides. Methods in Molecular Biology, vol 789. Humana Press. https://doi.org/10.1007/978-1-61779-310-3_22
Download citation
DOI: https://doi.org/10.1007/978-1-61779-310-3_22
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-309-7
Online ISBN: 978-1-61779-310-3
eBook Packages: Springer Protocols